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Abstract
Background: Repeat transarterial chemoembolisation (rTACE) is often required for hepatocellular carcinoma (HCC)
to achieve disease control, however, current practice guidelines regarding treatment allocation vary significantly.
This study aims to identify key factors associated with patient survival following rTACE to facilitate treatment
allocation and prognostic discussion.
Method: Patients with HCC undergoing rTACE at six Australian tertiary centers from 2009 to 2014 were included.
Variables encompassing clinical, tumour, treatment type and response factors were analysed against the primary
outcome of overall survival. Univariate analysis and multivariate Cox regression modelling were used to identify
factors pre- and post-TACE therapy significantly associated with survival.
Results: Total of 292 consecutive patients underwent rTACE with mainly Child Pugh A cirrhosis (61%) and BCLC
stage A (57%) disease. Median overall survival (OS) was 30 months (IQR 15.2–50.2) from initial TACE. On multivariate
analysis greater tumour number (p = 0.02), higher serum bilirubin (p = 0.007) post initial TACE, and hepatic
decompensation (p = 0.001) post second TACE were associated with reduced survival. Patients with serum AFP ≥
200 ng/ml following initial TACE had lower survival (p = 0.001), compared to patients with serum AFP level that
remained < 200 ng/ml post-initial TACE, with an overall survival of 19.4 months versus 34.7 months (p = 0.0001)
respectively.
Conclusion: Serum AFP level following initial treatment in patients undergoing repeat TACE for HCC is a simple and
useful clinical prognostic marker. Moreover, it has the potential to facilitate appropriate patient selection for rTACE
particularly when used in conjunction with baseline tumour burden and severity of hepatic dysfunction post-initial TACE.
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Background
The majority of patients with unresectable HCC (uHCC)
will undergo repeat transarterial chemoembolisation
(TACE) therapy to optimize treatment response, how-
ever a significant proportion are at risk for an adverse
outcome after repeat cycles due to either tumour pro-
gression or decline in hepatic reserve [1–4]. Whilst most
international guidelines provide inclusion criteria for ini-
tial TACE, clinical criteria for eligibility for repeat TACE
and factors predictive of poor outcomes are inadequately
defined [5, 6]. In this context, several scoring systems
have been developed to facilitate guidance in this area
such as ART (Assessment for Retreatment with TACE)
[7, 8] and ABCR (Alpha-fetoprotein, BCLC stage, Child-
Pugh class, and radiological response) [9] score. How-
ever, their clinical utility has been limited in part due to
their complexity and/or lack of applicability to the real
world setting where on demand TACE is commonly
employed and radiological response assessment has be-
come more refined [10–13].
Therefore, further studies are required to identify key
simple prognostic factors associated with overall survival
(OS) following repeat TACE so as to improve patient se-
lection and safety via the avoidance of unnecessary re-
peat procedures and unwanted side effects [6, 14]. Such
prognostic data will facilitate clinician decision making
and potentially improve patient survival as patients
undergo timely stage migration to the next treatment
option such as systemic therapy [15, 16].
In this study we analysed the prognostic factors associ-
ated with overall survival in patients undergoing repeat
TACE and in particular the impact of the tumour
marker alpha-fetoprotein (AFP). AFP is an established
prognostic marker of both poorer HCC phenotype and
more aggressive tumour biology [17–22]. While the
optimum cut off value varies significantly in published
literature on patients with HCC treated with TACE, it
has been suggested that higher pre-treatment AFP is as-
sociated with earlier recurrence and poorer overall sur-
vival [23–25].
Methods
Study population
We retrospectively identified patients with HCC who
had undergone TACE therapy from six tertiary centers
in Melbourne, Australia between January 2009 and
December 2014 using established HCC databases at each
hospital and review of electronic medical records. All pa-
tients had the diagnosis of HCC confirmed on biopsy or
established radiological criteria [26] and were deemed
suitable for TACE after review by the multi-disciplinary
team at the relevant hospital. Patients were included if
they were classified as BCLC stage A, B, or C with rela-
tively well preserved European Co-operative Oncology
Group (ECOG) performance status of 0–2. Subjects who
had undergone at least two cycles of TACE were in-
cluded, with the exception of those who were adminis-
tered TACE as a bridge to liver transplantation.
Pre- and post-TACE clinical, radiological and labora-
tory characteristics were recorded, including presence of
cirrhosis based on biochemical and radiological criteria
as previously described [16, 27]. Adverse events within 4
weeks of therapy were also recorded including hepatic
decompensation as defined by the development of asci-
tes, hepatic encephalopathy, hepatorenal syndrome or
upper GI bleeding [28, 29]. Following approval of a low-
risk application to the respective Institutional Ethics
Committees, data regarding patient and tumour charac-
teristics were collected for analysis, including clinical
and radiological response, as defined by the mRECIST
criteria [30, 31]. All patient data were de-identified prior
to collation and statistical analysis.
Primary outcome
Overall survival was calculated from the date of first
TACE treatment to either date of death or last clinical
follow-up, with censoring at 31st January 2019. The date
of death was obtained from either the patient hospital
records and MDT databases at each hospital or if miss-
ing from the Victorian Death and/or Cancer Registry.
Statistical analysis
Continuous data were summarised using mean (standard
deviation) or median (interquartile range) depending on
the underlying distribution of the data. Categorical data
were summarised using frequency tables, presenting the
subject counts and percentages. Comparisons between
groups (AFP < 200 versus ≥200 ng/ml) were made using
the Student’s t-test for normally distributed continuous
variables, Wilcoxon rank-sum test for non-normally dis-
tributed continuous variables and chi-square or Fisher’s
exact test as appropriate for categorical variables.
The Kaplan-Meier product-limit method was used to
plot survival as a function of time after treatment and to
determine the median survival times. Comparisons be-
tween survival curves were made using the log-rank test.
Univariate and multivariate analyses were performed via
Cox proportional hazards regression to assess the effects
of baseline clinical, liver disease, and tumour variables
(pre-TACE 2) as well as tumour response variables (be-
tween TACE-1 and TACE-2) on overall survival.
Multivariate models were developed using a stepwise
selection procedure and a backward elimination proced-
ure before undergoing assessment for clinical and bio-
logical plausibility. Results from the Cox regression
models were reported as hazard ratios (HR) and the
corresponding 95% confidence intervals (95% CI). All
reported P-values were two-sided with a P < 0.05
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indicating statistical significance. Analyses were per-
formed with the SAS software version 9.4 (SAS Institute,
Cary, NC, USA).
Results
Patient characteristics
A total of 431 patients received TACE for HCC from
2009 to 2014 inclusive, of these 292 received at least two
TACE treatments and were included in this study
(Table 1). This cohort comprised mainly of BCLC stage
A (57%) and B (39%) disease (Table 1). The majority of
patients were male (87%), of Caucasian background
(78%) and had predominantly alcohol (42%) or HCV
(41%) related chronic liver disease. At baseline most had
well compensated Child Pugh A (61%) cirrhosis with a
smaller proportion having Child Pugh B disease (30%).
Most patients had conventional TACE (cTACE) (79%)
with the remainder receiving drug eluting beads TACE
(DEB-TACE) (19%) or bland embolisation (TAE) (1%).
Incomplete radiological response of the target lesion fol-
lowing initial TACE was common, as defined by mRE-
CIST with majority having partial (43%), stable (9%) or
progressive (8%) disease. Repeat TACE was provided on
demand in all patients at a median interval of 2.5 months
(IQR 1.4–7.7) following initial TACE, with a few individ-
uals undergoing > 6 cycles. The most common complica-
tion of TACE observed was post-TACE syndrome (13%)
with liver decompensation occurring in 1% of patients.
Serum AFP data was available in 260 (89%) patients
prior to initial TACE, with the median baseline AFP
level being 19 ng/ml (IQR 5–174.5). Of these patients,
135 (52%) had levels below 20 ng/ml, 60 patients (23%)
had AFP ≥ 200 and 45 (17%) were ≥ 400 ng/ml prior to
initial TACE. Following initial TACE, 110 patients (42%)
had AFP of < 20 ng/ml, while 30 (12%) and 23 (9%) had
AFP ≥ 200 ng/ml and ≥ 400 ng/ml respectively. In total,
177 (61%) of the overall cohort had AFP data available
prior to both their first and second TACE for compara-
tive analysis. Of these 30 patients (17%) had an AFP ≥
200 ng/ml following initial TACE therapy and 147 (83%)
had an AFP < 200 ng/ml.
Overall survival
During a median follow-up of 28 months (IQR 14.8–
45.4) after the initial TACE, there were 82 (28%) patients
who died. The median overall survival from time of first
TACE therapy was 30months (IQR 15.2–50.2) (Fig. 1).
Predictors of overall survival
Univariate analysis
Univariate analysis compared all variables associated
with OS encompassing hepatic synthetic function,
tumour-related factors both pre- and post-initial TACE
and radiological response (mRECIST). Baseline variables
Table 1 Baseline characteristics of the cohort undergoing
repeat TACE therapy
Baseline Characteristics Overall cohort n = 292
Age (years), mean, (SD) 66 (10)
Male, n (%) 254 (87)
Female, n(%) 38 (13)
Ethnicity, n(%)
Caucasian 229 (78)
Asian 51 (17)
Other 12 (4)
Aetiology of Liver disease, n(%)
HCV / HBV / ETOH 120/58/122 (41/20/42)
NAFLD / Haemochromatosis/ other 67/12/14 (23/4/5)
BMI, mean (SD) 26 (24-30)
Serum markers, median (IQR)
AFP, ng/ml 19 (5-175)
ALT, U/L 49 (32-78)
Albumin, g/L 34 (31-39)
Bilirubin, μmol/L 18 (12-27)
INR 1.1 (1.0-1.3)
Creatinine, μmol/L 75 (65-87)
Na, mmol/L 139 (137-140)
Liver function, n (%)
Portal HTN / Ascites / HE 253/39/16 (87/13/5)
Child Pugh Score (A/B) 178/88/(61/30)
MELD score 9 (7-11)
ECOG (0/1), n (%) 127/165 (43/57)
Tumour Characteristics
Tumour Nodules (1/2/3/>3), n (%) 127/65/20/80 (43/22/7/27)
Tumour Size, cm (median, IQR) 3.3 ( 2.0-5.0)
Macrovascular invasion, n (%) 9 (3)
Extrahepatic spread, n (%) 5 (2)
BCLC stage (A/B/C), n (%) 166/113/13 (57/39/4)
TACE treatments (2/3/>3) n (%) 132/80/80 (45/27/27)
Type (cTACE / DEB TACE / TAE) 232/56/3 (79/19/1)
Selectivity
selective /superselective /non selective 197/48/43 (67/16/15)
mRECIST Response, n (%)
Complete/Partial 69/127 (24/43)
Stable/Progressive 26/22 (9/8)
Adverse Events, n (%)
Death 3 (1)
Post TACE syndrome/Decompensation 38/4 (13/1)
Renal dysfunction/other 3/12 (1/4)
Post TACE Treatment, n (%) 59 (20)
Resection/Ablation/PEI/SIRT 8/33/11/9 (3/11/4/3)
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pre-initial TACE associated with improved survival in
patients undergoing repeat TACE included single
tumour (p = 0.043), BCLC stage A (p = 0.026) and
higher serum albumin (p < 0.001) (Table 2a). In con-
trast, variables reflective of lower hepatic reserve prior
to initial and repeat TACE including higher CP score
(p < 0.001), serum bilirubin (p < 0.001), liver decom-
pensation (p < 0.001) and ascites (p < 0.001) were sig-
nificantly associated with reduced OS. Of note, renal
dysfunction following the second TACE was associ-
ated with the highest risk of mortality [HR 3.46
(1.07–11.19), p = 0.035] (Table 2b).
Analysis of serum AFP as a continuous variable dem-
onstrated a higher serum AFP following initial TACE
was associated with lower survival (p < 0.001) in pa-
tients undergoing repeat TACE (data not shown). For
increased interpretability of HR and CI the application
of serum cut-off levels of 200 ng/ml and 400 ng/ml,
demonstrated a significant relationship between both
pre and post treatment serum AFP and overall survival
(Table 3).
Multivariate analysis
On multivariate analysis, factors significantly associated
with lower survival in patients undergoing repeat TACE
included an increase in number of tumour nodules at
baseline (p = 0.02), a serum AFP ≥ 200 ng/ml (p = 0.001)
and higher bilirubin following initial TACE (p = 0.007),
and liver decompensation following repeat TACE (p =
0.001) (Table 4).
Relationship between AFP and overall survival
On further subgroup analysis patients with a higher
serum AFP ≥ 200 ng/ml following initial TACE had a
significantly lower overall survival with median OS of
18.2 months (IQR 9.2 to 26.1) compared to those with
serum AFP < 200 ng/ml of 31.1 months (IQR 18.7 to
55.4) (Fig. 2). Further comparative analysis of the charac-
teristics of these two subgroups (Table 5) found that pa-
tients with AFP ≥ 200 ng/ml had greater tumour burden
at baseline as identified by BCLC stage C (p = 0.017), lar-
ger mean tumour size (p = 0.002), and macrovascular in-
vasion (p = 0.035) compared to patients with AFP < 200
ng/ml following initial TACE. In comparison, patients
with serum AFP < 200 ng/ml were less likely to have
underlying HCV (p = 0.004) or HBV (0.05), higher rates
of T2DM (p = 0.05) and lower inflammatory response
following TACE with lower serum neutrophils (p =
0.001) and ALT (p = 0.03).
To further explore the relationship between OS and
AFP levels, we analysed the survival of patients accord-
ing to the pattern of change in serum AFP levels < and
≥ 200 ng/ml pre- and post-initial TACE. Notably, the
median survival of patients with an AFP ≥ 200 ng/ml
both pre- and post-initial was similar to subjects whose
level fell below 200 ng/ml after TACE (18.2 vs 19.9months)
(Table 6). In comparison, the median OS of patients whose
AFP remained < 200 ng/ml both pre- and post-initial TACE
was significantly higher at 34.7months compared to the
groups whose AFP level was either ≥ 200 ng/ml at baseline
or increased to ≥ 200 ng/ml after initial TACE (p = 0.0001)
(Table 6).
Discussion
TACE is an effective treatment in eligible patients with
uHCC, however the majority of patients treated with
TACE will require repeat therapy due to a partial re-
sponse or tumour recurrence. Treatment outcomes after
TACE are influenced by both the severity of underlying
liver dysfunction and tumour burden [1–3, 32], and as
such the indications and criteria for repeat TACE re-
main variably defined and adopted in International
guidelines [5, 26, 33, 34]. We therefore explored the fac-
tors associated with overall survival in patients having
repeat TACE in a real-world multicenter cohort focusing
particularly on the prognostic role of serum AFP level.
Serum AFP as a marker of tumour burden has been
previously proposed as a prognostic marker in patients
undergoing TACE for uHCC [35–38]. However, the
prognostic role of serial changes in serum AFP levels fol-
lowing TACE has been controversial as not all HCC
produce AFP, and false positive results not infrequently
occur such as in active viral hepatitis [36, 39–41]. Con-
sequently, a wide variety of serum cut off values have
been postulated ranging from 20 to 400 ng/ml, as well as
variations in serum AFP response ranging from 20 to
50% based on the AUROC of the derivation cohort
[42–48]. Notably, application of these percentage
change values in pre and post treatment AFP had no
significant prognostic effect on OS in our cohort, and
may reflect the inherent differences in our characteristics
Fig. 1 Kaplan Meier survival analysis of the overall cohort
undergoing repeat TACE (n = 292)
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at baseline and also the inability of the delta value to cap-
ture the wide variations in serum AFP levels associated
with HCC [49].
In contrast several recent studies including a meta-
analysis have demonstrated a significant association of
specific serum levels of AFP with HCC treatment out-
comes including treatment response and overall
survival [43, 50, 51]. In a recent prognostic model
Wang et al. found the serum AFP of 400 ng/ml was a
useful cut off value in a population with predomin-
antly HBV related liver disease [38, 45]. They found
the AFP response following TACE independently asso-
ciated with prognosis in BCLC stage B patients, how-
ever further analysis regarding combination therapy
Table 2 Univariate analysis of variables associated with overall survival in patients undergoing repeat TACE, with baseline variables
(a) and subsequent to initial TACE (b)
Overall cohort n = 292
Hazard Ratio Lower 95% CI Higher 95% CI P value
Pre -TACE
Variable
Single Tumour 0.76 0.59 1.00 0.043
Albumin, g/L 0.96 0.94 0.98 <0.001
Bilirubin, μmol/L 1.02 1.01 1.03 <0.001
Ascites 1.94 1.35 2.78 <0.001
Hepatic Encephalopathy 1.70 0.99 2.90 0.048
BCLC stage A 0.75 0.58 0.97 0.026
BCLC stage B 1.36 1.04 1.77 0.020
Child Pugh Score (5/6/7/8/9) 1.25 1.13 1.39 <0.001
AFP ≥ 200 ng/ml 1.48 1.07 2.04 0.015
Post-TACE
Variable
Post 1st TACE
AFP ≥ 200 ng/ml 2.19 1.43 3.36 <0.001
Albumin, g/L 0.95 0.93 0.98 <0.001
Bilirubin, μmol/L 1.02 1.01 1.03 <0.001
Na, mmol/L 0.95 0.91 0.99 0.010
INR 1.70 1.12 2.59 0.012
MELD score 1.07 1.02 1.11 0.004
Child Pugh Score (5/6/7/8/9) 1.29 1.16 1.43 <0.001
Ascites 1.66 1.17 2.35 0.004
Post 2nd TACE
Decompensation 3.39 1.85 6.21 <0.001
Renal dysfunction 3.46 1.07 11.19 0.035
Combination therapy 0.65 0.46 0.91 0.011
Ablation 0.56 0.35 0.88 0.011
Resection 0.27 0.10 0.76 0.011
Table 3 Univariate analysis of pre and post initial TACE serum AFP levels and association with overall survival
Variable n % Hazard Ratio Lower 95% CI Higher 95% CI P value
Baseline AFP ≥ 200 ng/ml 260 23% 1.48 1.07 2.04 0.015
Post initial TACE AFP ≥ 200 ng/ml 177 17% 2.19 1.43 3.36 <0.001
Baseline AFP ≥ 400 ng/ml 260 17% 1.36 0.95 1.95 0.088
Post Initial TACE AFP ≥ 400 ng/ml 177 13% 2.41 1.49 3.90 <0.001
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with other treatments such as ablation or systemic
therapies was not available.
When applied to our cohort, we found serum AFP cut
off level of 200 ng/ml had the greatest stratification com-
pared to an AFP < 20 ng/ml that was seen in 135 (52%)
and AFP < 400 ng/ml in 215 (83%) of patients. This AFP
value has the potential advantage over the lower cut off
value of < 20 ng/ml in being less likely to include those
with an elevated level due to active liver disease such as
such as with chronic viral hepatitis [36, 41]. A serum
AFP < 200 ng/ml was a significant prognostic marker both
pre and post initial TACE associated with better overall
survival outcomes (Fig. 2). Patients that maintained an
AFP < 200 ng/ml at baseline and following initial TACE
had a significantly better survival outcome (p = 0.0001)
compared to patients that had a higher baseline AFP ≥2
00 ng/ml regardless of a post treatment change in levels.
The poorer prognosis in patients with AFP ≥ 200 ng/ml
following TACE may relate to the greater tumour burden
at baseline including tumour size (p = 0.002) and macro-
vascular invasion (p = 0.035) along with greater inflamma-
tory response to treatment with higher serum ALT (p =
0.03) and neutrophil count (p = 0.001). Further detailed
analysis of serum AFP pre and post TACE is limited by
small number of patients in each subgroup.
Our results are consistent with recent updates in inter-
national guidelines [26, 52] that have endorsed the
revised cut off of 200 ng/ml from the previously used
400 ng/ml due to superior sensitivity and specificity and
nearly 99% positive predictive value [36, 49, 53]. In par-
ticular explant studies have demonstrated higher AFP
levels ≥200 ng/ml are associated with higher risk of both
microvascular and macrovascular invasion, along with
poorly differentiated tumours as was demonstrated in
our analysis (Table 3) [21, 54]. However, the reduced
availability of repeat AFP data in 61% of our overall co-
hort limits the generalisability of our findings particu-
larly in cases of non-AFP producing HCC.
Along with AFP level, we found like others on multi-
variate analysis that markers of both hepatic reserve and
tumour burden are key prognostic markers being associ-
ated with poorer survival following repeat TACE [14,
55–59]. In particular, decreasing liver reserve had the
greatest impact on mortality in our cohort with post
TACE liver failure and decompensation associated with
the highest risk of reduced survival [HR 4.50, (95% CI
1.86–10.89), p = 0.001], (p = 0.001). Although this oc-
curred in only 1% of our patients and is generally
thought to be low in incidence (2–7%) [60–62], the fre-
quency of liver decompensation may be as high as 18%
following TACE depending on the definition used
[30, 63–65]. We also found like others that decline in
liver function as measured by higher serum bilirubin
prior to repeat TACE was associated with reduced survival
[66–68]. This again highlights the prognostic importance
of liver reserve following TACE because discontinuation
of TACE due to liver decompensation and/or biochemical
decline carries a poorer prognosis than when it is due to
radiological progression. Indeed, most patients with sig-
nificant hyperbilirubinaemia are unsuitable for or intoler-
ant of further therapies such as systemic therapy and are
managed with best supportive care [69–71].
In addition, the number of tumour nodules prior to
initial TACE was a significant and independent prognos-
tic marker following repeat TACE in our cohort being
associated with a higher risk of mortality. This is similar
to the findings of several previous studies [57, 72, 73].
Furthermore, greater tumour size at baseline was signifi-
cantly associated with higher serum AFP ≥ 200 ng/ml
following initial TACE which was one of the key prog-
nostic determinants associated with lower OS on multi-
variate analysis (Table 4).
Table 4 Multivariate analysis of variables associated with overall survival in patients undergoing repeat TACE
Overall cohort n = 292
Variable Hazard Ratio Lower 95% CI Higher 95% CI P value
Baseline tumour number, 1, 2,3, > 3 1.18 1.03 1.36 0.020
Bilirubin post TACE 1 1.02 1.00 1.03 0.007
AFP ≥ 200 ng/ml post TACE 1 2.13 1.34 3.40 0.001
Decompensation post TACE 2 4.50 1.86 10.89 0.001
Fig. 2 Kaplan Meier survival analysis of patients with an serum AFP
above or below 200 ng/ml following initial TACE (AFP1)
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As noted above an important limitation of our study
was the reduced availability of serial AFP levels before
and after the initial TACE to explore the relationship
with survival further. However, there was only minimal
differences in the characteristics in those without follow
up AFP levels, with lower rates of HCV infection (p =
0.024), higher NAFLD (p = 0.03), and higher proportion
of single HCC (p = 0.03) (data not shown). Other study
limitations include the retrospective analysis of data with
resultant variations in the timing of serum collection pre
and post TACE as well as variations in on-site specific
protocols, and this may impact on the interpretation of
results that are influenced by post treatment hepatic dys-
function and inflammation such as serum AFP [36, 41].
Our study also includes patients undergoing combin-
ation therapies with TACE and a small number of BCLC
stage C (4%) patients that underwent TACE outside of
current guidelines, consistent with contemporary real-
world studies analysing global patterns of TACE utilisa-
tion [15, 16]. Despite these limitations this is a large
study analysing prognostic factors in patients undergoing
repeat TACE on demand for uHCC over a significant
period of 6 years across six large tertiary referral centres.
As such these results have greater clinical relevancy to
current clinical practice as the data incorporates varia-
tions in patient selection, TACE type (conventional or
DEB), and technique (selective or super selective).
Conclusions
Patient selection for repeat TACE requires a careful bal-
ance between the risk of complications, and benefits,
with evaluation of both pre and post treatment factors
associated with poor outcomes. These include higher
baseline tumour burden, and decline in liver reserve. In
particular, serum AFP is a useful prognostic marker for
risk stratification, with an AFP ≥ 200 ng/ml post initial
TACE associated with significantly poorer outcomes in
those undergoing repeat TACE.
Appendix
mRECIST Definition [31]
Radiological response will be defined according to stand-
ard EASL criteria using modified RECIST (mRECIST)
criteria as assessed by triphasic CT scan and/or MRI
scan and include the following:
Complete response (CR): Disappearance of any intra-
tumoural arterial enhancement in all target lesions
Partial response (PR): At least a 30% decrease in the
sum of the diameters of viable (enhancement in the ar-
terial phase) target lesions
Stable disease (SD): Any cases that do not qualify for
either PR or progressive disease (PD)
Progressive disease (PD): An increase of at least 20%
in the sum of the diameters of viable (enhancing) target
lesions, taking as reference the smallest sum of the di-
ameters of viable (enhancing) target lesions recorded
since treatment started.
Table 5 Characteristics of patients following initial TACE with AFP ≥ 200 ng/ml vs. < 200 ng/ml
Repeat serum AFP subgroup n = 177
Variable n AFP < 200 ng/ml n AFP ≥ 200 ng/ml P value
Pre-TACE, % (n)
Caucasian 147 83.7% (123) 30 63.3% (19) 0.011
HCV 147 41.5% (61) 30 70% (21) 0.004
HBV 147 17.7% (26) 30 33.3% (10) 0.05
T2DM 147 34.7% (51) 30 16.7% (5) 0.05
BCLC stage C 147 2% (3) 30 13.3% (4) 0.017
Macrovascular invasion 147 1.4% (2) 30 10% (3) 0.035
tumour size, (cm), mean (SD) 147 3.84 (2.55) 30 5.64 (3.89) 0.002
Post initial TACE, median (IQR)
Neutrophils, x10^9/L 91 2.9 [2.3-3.72] 23 4.2 [2.9-5.1] 0.001
ALT, U/L 146 38.5 [24-72] 29 65 [34-100] 0.03
Na, mmol/L 145 138 [136-140] 28 137 [135-139] 0.048
Table 6 Median survival time by AFP level of 200 ng/ml at
baseline and post initial TACE
AFP groups n Median Survival time,
months (IQR)
P value
AFP0 < 200 and AFP1 < 200 135 34.7 (19.9 - 56.1) 0.0001
AFP0 < 200 and AFP1 ≥ 200 5 19.4 (14.2 - 29.6)
AFP0 ≥ 200 and AFP1 < 200 12 19.9 (13.3 - 27.7)
AFP0 ≥ 200 and AFP1 ≥ 200 25 18.2 (9.2 - 26.1)
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